Total Payments
$967,203
2024 Payments
$93,909
Companies
24
Transactions
755
Medicare Patients
1,148
Medicare Billing
$751,832
Payment Breakdown by Category
Other$479,848 (49.6%)
Consulting$317,388 (32.8%)
Research$77,687 (8.0%)
Travel$46,303 (4.8%)
Education$28,257 (2.9%)
Food & Beverage$17,720 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $463,851 | 184 | 48.0% |
| Consulting Fee | $317,388 | 88 | 32.8% |
| Unspecified | $77,687 | 49 | 8.0% |
| Travel and Lodging | $46,303 | 100 | 4.8% |
| Education | $28,257 | 32 | 2.9% |
| Food and Beverage | $17,720 | 294 | 1.8% |
| Honoraria | $12,002 | 6 | 1.2% |
| Grant | $2,000 | 1 | 0.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,995 | 1 | 0.2% |
Payments by Type
General
$889,516
706 transactions
Research
$77,687
49 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $201,982 | 163 | $0 (2024) |
| Biogen, Inc. | $155,731 | 100 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $129,836 | 110 | $0 (2024) |
| GENZYME CORPORATION | $100,439 | 92 | $0 (2024) |
| Genentech USA, Inc. | $92,001 | 79 | $0 (2023) |
| TG Therapeutics, Inc. | $69,897 | 54 | $0 (2024) |
| Celgene Corporation | $56,201 | 38 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $32,488 | 32 | $0 (2024) |
| F. Hoffmann-La Roche AG | $31,789 | 15 | $0 (2024) |
| Horizon Therapeutics plc | $30,855 | 23 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $93,909 | 70 | TG Therapeutics, Inc. ($42,044) |
| 2023 | $123,136 | 87 | EMD Serono, Inc. ($50,843) |
| 2022 | $89,533 | 72 | EMD Serono, Inc. ($26,517) |
| 2021 | $120,319 | 73 | Novartis Pharmaceuticals Corporation ($18,717) |
| 2020 | $140,708 | 90 | Novartis Pharmaceuticals Corporation ($39,150) |
| 2019 | $108,929 | 128 | EMD Serono, Inc. ($27,096) |
| 2018 | $150,405 | 127 | Biogen, Inc. ($35,210) |
| 2017 | $140,263 | 108 | Biogen, Inc. ($45,079) |
All Payment Transactions
755 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,555.00 | General |
| Category: Neurology | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,800.00 | General |
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $70.18 | General |
| Category: Neurology | ||||||
| 12/05/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $45.75 | General |
| 11/22/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $1,381.39 | General |
| Category: Neurology | ||||||
| 11/22/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $65.00 | General |
| Category: Neurology | ||||||
| 11/19/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,175.00 | General |
| Category: Neurology | ||||||
| 11/06/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,387.50 | General |
| Category: Immunology | ||||||
| 11/06/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | In-kind items and services | $1,281.40 | General |
| Category: Immunology | ||||||
| 11/06/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 10/25/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $31.40 | General |
| Category: Rare Disease | ||||||
| 10/25/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $28.54 | General |
| 10/15/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,737.50 | General |
| Category: Immunology | ||||||
| 10/15/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | In-kind items and services | $2,235.00 | General |
| Category: Immunology | ||||||
| 10/15/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | In-kind items and services | $291.33 | General |
| Category: Immunology | ||||||
| 10/15/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $123.17 | General |
| Category: Immunology | ||||||
| 10/15/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $29.30 | General |
| Category: Immunology | ||||||
| 10/10/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $842.25 | General |
| Category: Neurology | ||||||
| 10/10/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $65.00 | General |
| Category: Neurology | ||||||
| 10/09/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,387.50 | General |
| Category: Immunology | ||||||
| 10/09/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: Neurology | ||||||
| 10/09/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | In-kind items and services | $1,490.00 | General |
| Category: Immunology | ||||||
| 10/09/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $122.55 | General |
| Category: Immunology | ||||||
| 10/08/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,475.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $15,000 | 3 |
| BALANCING POTENTIAL BENEFITS AND RISKS OF BRUTON S TYROSINE KINASE INHIBITOR THERAPIES IN MULTIPLE SCLEROSIS DURING THE COVID-19 PANDEMIC A REVIEW. | F. Hoffmann-La Roche AG | $10,809 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $8,937 | 6 |
| BALANCING POTENTIAL BENEFITS AND RISKS OF BRUTON S TYROSINE KINASE INHIBITOR THERAPIES IN MULTIPLE SCLEROSIS DURING THE COVID-19 PANDEMIC | F. Hoffmann-La Roche AG | $6,969 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $5,290 | 3 |
| OUTCOMES RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $4,450 | 2 |
| Publication support research related | Novartis Pharma AG | $2,808 | 2 |
| Ocrelizumab in Patients with RMS | F. Hoffmann-La Roche AG | $2,754 | 2 |
| PUBLICATION SUPPORT IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $2,552 | 1 |
| The patient impact of 11 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies | F. Hoffmann-La Roche AG | $2,242 | 2 |
| Fenebrutinib, a noncovalent, reversible, Brutons tyrosine kinase inhibitor, potently blocks neuroinflammation induced by Fc? receptor activation in human microglial systems: implications for multiple sclerosis treatment | F. Hoffmann-La Roche AG | $2,153 | 2 |
| Roll Over Protocol ROP for WA21092 OPERA I WA21093 OPERA II and WA25046 ORATORIO studies | F. Hoffmann-La Roche AG | $2,021 | 1 |
| A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA Treatment in Patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modif | GENZYME CORPORATION | $1,603 | 2 |
| A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MULTIPLE SCLEROSIS , A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $1,574 | 2 |
| A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis, A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis, A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled | F. Hoffmann-La Roche AG | $1,433 | 2 |
| A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA Treatment In patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modif | GENZYME CORPORATION | $1,222 | 1 |
| Long-Term Efficacy of Ocrelizumab up to 8-Years in RMS Patients in the OPERA Study and Open-Label Extension Using Repeated Event Analysis | F. Hoffmann-La Roche AG | $1,207 | 1 |
| Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) Demonstration Project | Biogen, Inc. | $987.65 | 8 |
| A prospective observational cohort study in patients with relapsing multiple sclerosis to assess patient safety during and after LEMTRADA (alemtuzumab) infusions of the first treatment course | GENZYME CORPORATION | $893.33 | 1 |
| MSPT Device Usability Study | Biogen, Inc. | $781.41 | 1 |
| 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-Term Efficacy and Safety Clinical Trial Data | F. Hoffmann-La Roche AG | $628.05 | 1 |
| A prospective, 24-month observational study to evaluate patient reported outcomes and safety after Lemtrada treatment in patients with relapsing multipe sclerosis switching from a prior disease modify | GENZYME CORPORATION | $402.00 | 1 |
| A Prospective, 24-month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA Treatment in Patients With Relapsing Multiple Sclerosis Switching From a Prior Disease Modif | GENZYME CORPORATION | $353.33 | 1 |
| A prospective, 24-month observational study to evaluate patient reported outcomes and safety after LETRADA treatment in patients with relapsing multiple sclerosis switching from a prior disease modify | GENZYME CORPORATION | $328.91 | 1 |
| A prospective, 24-month observational study to evaluate patient reported outcomes and safety after lemtrada treatment in patients with relapsing multiple sclerosis switching from a prior disease modif | GENZYME CORPORATION | $289.09 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 265 | 23,120 | $394,987 | $149,720 |
| 2022 | 9 | 260 | 33,638 | $566,896 | $204,693 |
| 2021 | 9 | 343 | 33,323 | $581,938 | $208,720 |
| 2020 | 9 | 280 | 31,662 | $512,505 | $188,699 |
Total Patients
1,148
Total Services
121,743
Medicare Billing
$751,832
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 24 | 22,750 | $295,750 | $111,832 | 37.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 78 | 97 | $24,444 | $12,154 | 49.7% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2023 | 15 | 37 | $17,353 | $5,064 | 29.2% |
| 64642 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | Office | 2023 | 23 | 45 | $18,540 | $5,042 | 27.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 36 | 36 | $12,924 | $4,849 | 37.5% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 34 | 77 | $8,208 | $4,449 | 54.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 37 | 41 | $7,667 | $3,646 | 47.6% |
| 64643 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | Office | 2023 | 18 | 37 | $10,101 | $2,685 | 26.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 26 | 25,800 | $335,400 | $122,751 | 36.6% |
| J0586 | Injection, abobotulinumtoxina, 5 units | Office | 2022 | 13 | 7,500 | $142,500 | $47,518 | 33.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 71 | 80 | $20,160 | $10,485 | 52.0% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2022 | 20 | 45 | $21,105 | $5,988 | 28.4% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2022 | 34 | 83 | $8,964 | $4,944 | 55.2% |
| 64642 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | Office | 2022 | 21 | 40 | $16,480 | $4,572 | 27.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 43 | $7,994 | $3,668 | 45.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $6,103 | $2,634 | 43.2% |
| 64643 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | Office | 2022 | 19 | 30 | $8,190 | $2,131 | 26.0% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 30 | 25,830 | $335,790 | $121,112 | 36.1% |
| J0586 | Injection, abobotulinumtoxina, 5 units | Office | 2021 | 15 | 7,060 | $134,140 | $44,765 | 33.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 74 | 82 | $20,610 | $9,855 | 47.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 83 | 93 | $17,297 | $7,767 | 44.9% |
| 64642 | Injection of chemical for destruction of nerve muscles on one arm or leg, 1-4 muscles | Office | 2021 | 25 | 54 | $22,248 | $6,201 | 27.9% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Office | 2021 | 39 | 81 | $8,748 | $5,116 | 58.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 31 | 31 | $11,129 | $4,941 | 44.4% |
| 64644 | Injection of chemical for destruction of nerve muscles on one arm or leg, 5 or more muscles | Office | 2021 | 17 | 35 | $16,415 | $4,837 | 29.5% |
About Dr. Jacqueline Nicholas, M.D
Dr. Jacqueline Nicholas, M.D is a Neurology healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2008. The National Provider Identifier (NPI) number assigned to this provider is 1740457886.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jacqueline Nicholas, M.D has received a total of $967,203 in payments from pharmaceutical and medical device companies, with $93,909 received in 2024. These payments were reported across 755 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($463,851).
As a Medicare-enrolled provider, Nicholas has provided services to 1,148 Medicare beneficiaries, totaling 121,743 services with total Medicare billing of $751,832. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology
- Location Columbus, OH
- Active Since 05/08/2008
- Last Updated 08/02/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1740457886
Products in Payments
- TYSABRI (Biological) $93,480
- BRIUMVI (Drug) $60,487
- LEMTRADA (Drug) $57,839
- OCREVUS (Biological) $56,973
- Mavenclad (Drug) $54,222
- ZEPOSIA (Drug) $54,196
- GILENYA (Drug) $43,117
- Non-Covered Product (Drug) $35,341
- UPLIZNA (Drug) $30,855
- KESIMPTA (Drug) $29,706
- ARZERRA (Drug) $26,056
- MAVENCLAD (Drug) $24,637
- Ozanimod (Drug) $17,093
- AUBAGIO (Drug) $17,048
- Mavenclad (Biological) $16,965
- TECFIDERA (Drug) $15,776
- Ocrevus (Biological) $13,285
- Soliris (Drug) $7,607
- Rebif (Biological) $6,382
- MAYZENT (Drug) $5,287
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Columbus
Kenneth Mankowski, Do, DO
Neurology — Payments: $1.9M
Neurology $1.9M
Dr. Aaron Boster, Md, MD
Neurology — Payments: $1.9M
Neurology $1.9M
Danielle Becker, Md, MD
Neurology — Payments: $1.3M
Neurology $1.3M
Dr. Jonathan Liss, M.d, M.D
Neurology — Payments: $468,143
Neurology $468,143
Jerry Mendell, Md, MD
Neurology — Payments: $371,804
Neurology $371,804
Dr. Andrew Smith, M.d, M.D
Neurology — Payments: $277,150
Neurology $277,150